Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 30 of 5804
-
Chewing gum to prevent premature births? major trial underway in malawi
Prevention Recruiting nowThe ground-breaking Prevention of Prematurity and Xylitol (PPaX) cluster randomized controlled clinical trial was conducted in Lilongwe, Malawi and enrolled approximately 10,069 pregnant individuals seeking to evaluate the impact of xylitol-containing chewing gum compared to no c…
Phase: PHASE2, PHASE3 • Sponsor: University of Washington • Aim: Prevention
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to wipe out early triple-negative breast cancer before surgery
Disease control Not yet recruitingCamrelizumab + Chemoradiotherapy for Early TNBC Sponsor/Leading Center: Tianjin Medical University Cancer Institute and Hospital Study Type: Single-arm, single-center, Phase Ⅱ clinical study Planned Enrollment: 43 patients Eligible Population 18-75-year-old female patients with n…
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug votoplam enters final phase 3 trial for Huntington's disease
Disease control Recruiting nowThe purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Thera…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Brain pacemaker trial aims to cut seizures in kids with severe epilepsy
Disease control Recruiting nowThe CADET Trial will investigate the effectiveness of deep brain stimulation (DBS) to reduce the frequency of seizures in children with Lennox-Gastaut syndrome (LGS). The CADET Trial will use a non-CE/UKCA marked device - the Picostim DBS system. The SMART-DBS study is a sub-stu…
Phase: NA • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New oral drug could slow MS progression in major trial
Disease control Recruiting nowOrelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 mo…
Phase: PHASE3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Ultrasound opens brain barrier to supercharge immune attack on deadly tumor
Disease control Recruiting nowThis is a phase 1 study for patients with newly diagnosed MGMT unmethylated IDH wild-type glioblastoma utilizing autologous activated T-cells armed with bispecific antibody (EGFR-BATs) that recognize the tumor. The investigators hypothesized that the combination of infusions of E…
Phase: PHASE1 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New weekly shot could help obese diabetics shed pounds and control blood sugar
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesi…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New mRNA shot targets bird flu: 4,000 volunteers needed
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:03 UTC
-
New meningitis vaccine trial aims to shield babies from deadly infection
⭐️ VACCINE ⭐️ Not yet recruitingThe goal of this clinical trial is to evaluate the immunogenicity, safety, and immune persistence of the primary series of an investigational group ACYW135 meningococcal conjugate vaccine, as well as the immunogenicity and safety of a booster dose administered at 12 months of age…
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:03 UTC
-
New combo aims to stop KRAS-Mutant lung cancer from coming back
Disease control Recruiting nowThis is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New heart valve device aims to fix tricuspid leak without open surgery
Disease control Recruiting nowPivotal trial to evaluate the safety and effectiveness of the TruGamma tricuspid valve replacement system
Phase: NA • Sponsor: Jiangsu Trulive Medical Co., Ltd • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy aims to slash liver cancer recurrence after surgery
Disease control Not yet recruitingHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates reaching 50% and 70%, respectively. Currently, no st…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could CAR-T cells tame tough autoimmune diseases?
Disease control Recruiting nowThis is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH receive umbilical cord blood CD19-BCMA CAR …
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Immune cells engineered to fight deadly childhood brain tumors enter human trials
Disease control Recruiting nowThe purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Immunotherapy may replace chemo in anal cancer treatment
Disease control Recruiting nowThis is a prospective, multicenter, open-label, phase III randomized controlled clinical trial designed to evaluate the efficacy and safety of replacing the traditional chemotherapeutic drug mitomycin with the PD-1 inhibitor sintilimab in definitive chemoradiotherapy for limited-…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
CAR t therapy aims to snuff out hidden lymphoma cells
Disease control Recruiting nowThe goal of the main clinical research study is to learn if treatment with a chimeric antigen receptor (CAR) T-cell therapy called lisocabtagene maraleucel (liso-cel) can help to prevent recurrence of large B-cell cell lymphoma in patients who have achieved complete response (CR)…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for tough breast cancer: phase 3 trial launches
Disease control Recruiting nowPrimary Endpoint of this Study: To compare Progression-Free Survival (PFS) (as assessed by a Blinded Independent Review Committee \[BIRC\] based on Response Evaluation Criteria in Solid Tumors \[RECIST v1.1\]) between JSKN016 and Treatment of Physician's Choice (TPC) in particip…
Phase: PHASE3 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New weekly shot shows promise for major weight loss in major trial
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Ty…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Lab-Grown cells could free diabetics from insulin shots
Disease control Not yet recruitingThis is a single-arm, open-label clinical trial designed to assess the safety and therapeutic efficacy of iPSC-derived islet cell infusion in patients with diabetes mellitus.
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
One-Shot gene therapy could replace frequent eye injections for wet AMD
Disease control Recruiting nowThis is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitre…
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC